Key facts
- It has raised $5.3M; the latest was Later Stage VC ($3.1M) in Feb 2025.
- Notable investors include MedTech Innovator, European Commission, Elaia Partners, BioTools Innovator, Faber Ventures — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Zymvol
- ·The full record, as it builds
Funding rounds
No funding rounds for Zymvol are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Zymvol
Developer of industrial enzymes designed to meet precise industrial requirements. The company's enzymes are discovered through computer simulation to make them accessible to any company in need of biocatalysts and improve those that do not have automated laboratory screening processes, enabling clients to avail customized biocatalysts.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2017
- Employees
- 32
- Website
- zymvol.com/
- Ownership
- Privately Held (backing)
Zymvol doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Zymvol shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Zymvol in its N-PORT filings yet. We sweep new filings monthly.